| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
NBD-556 targets the HIV-1 envelope glycoprotein gp120. It binds to the CD4-binding site on gp120, mimicking the interaction of the CD4 receptor. By binding to gp120, NBD-556 induces conformational changes that inhibit the interaction between gp120 and CD4, thereby blocking viral entry. This mechanism prevents HIV-1 from entering host cells. The compound shows activity against various HIV-1 strains.
|
|---|---|
| ln Vitro |
NBD-556 (1-100 μM) suppresses the fusion of cells and viruses mediated by the HIV-1 envelope [1]. The laboratory-adapted HIV-1 IIIB, MN, and V32 strains are inhibited from infecting MT-2 cells by NBD-556, with IC50 values of 6.5, 15.9, and 5.3 µM, respectively [1]. NBD-556 (1-100 μM) has an IC50 of 22.6 μM and suppresses CD4-dependent viruses in a dose-dependent manner [1].
In vitro, NBD-556 inhibits HIV-1 entry by blocking the interaction between gp120 and CD4. It shows activity against various HIV-1 strains. The compound's binding to gp120 and antiviral activity have been characterized in biochemical and cell-based assays. Detailed in vitro data are available in the primary literature. NBD-556 is a valuable tool for studying HIV-1 entry mechanisms. |
| ln Vivo |
In vivo data for NBD-556 are limited in publicly available sources. Based on its in vitro anti-HIV-1 activity, the compound is expected to be useful for in vivo studies of HIV-1 infection. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic profile. The compound is a research tool for antiviral applications.
|
| Enzyme Assay |
In vitro HIV-1 entry inhibition assays for NBD-556 typically use HIV-1 pseudoviruses or replication-competent viruses and susceptible cell lines (e.g., TZM-bl cells). The compound is dissolved in DMSO and diluted in culture medium. Cells are pre-treated with NBD-556 at various concentrations (0.001-100 μM) for 30-60 minutes, followed by virus addition. Viral entry is assessed by measuring reporter gene expression (e.g., luciferase) or viral replication. IC₅₀ values are calculated from dose-response curves. Controls include vehicle and known entry inhibitors. Binding to gp120 is assessed by ELISA or surface plasmon resonance.
|
| Cell Assay |
For cell-based assays, susceptible cell lines (e.g., TZM-bl, Jurkat) are cultured in appropriate medium. Cells are seeded in multi-well plates and pre-treated with NBD-556 at various concentrations for 30-60 minutes. HIV-1 pseudoviruses or replication-competent viruses are added. Viral entry is assessed by measuring reporter gene expression or viral replication. Cell viability is assessed by MTT or CellTiter-Glo. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, NBD-556 may be administered to animals for antiviral efficacy studies. The compound is formulated in a suitable vehicle. For HIV-1 infection models, humanized mice or other susceptible models are infected and treated with NBD-556 at various regimens. Endpoints include viral load reduction, CD4 cell count, and survival. Blood samples are collected for pharmacokinetic analysis. All procedures follow institutional guidelines.
|
| ADME/Pharmacokinetics |
NBD-556 (MW 353.42, C₁₉H₂₃N₃O₄) is an HIV-1 entry inhibitor. The compound is soluble in DMSO. Detailed pharmacokinetic parameters are not extensively reported in publicly available sources. The compound is typically stored at -20°C. It is for research purposes. Further ADME studies are needed to fully characterize its pharmacokinetic profile.
|
| Toxicity/Toxicokinetics |
NBD-556 is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions. Toxicity data are limited in publicly available sources.
|
| References |
[1]. Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology. 2005 Sep 1;339
[2]. Schon A, et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry. 2006 Sep 12;45(36):10973-10980. |
| Additional Infomation |
NBD-556 is a research-grade CD4-mimetic HIV-1 entry inhibitor for studying viral entry mechanisms and antiviral drug discovery. Its primary applications include virology, HIV research, and drug discovery. The compound is not approved for clinical use. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves binding to gp120 and blocking CD4-gp120 interaction.
|
| Molecular Formula |
C17H24CLN3O2
|
|---|---|
| Molecular Weight |
337.848
|
| Exact Mass |
337.156
|
| CAS # |
333353-44-9
|
| Related CAS # |
333353-44-9;NBD-556 HCl;
|
| PubChem CID |
1570601
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.073
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
23
|
| Complexity |
441
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C(NC1CC(C)(NC(C)(C1)C)C)=O)NC2=CC=C(C=C2)Cl
|
| InChi Key |
ZKXLQCIOURANAD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H24ClN3O2/c1-16(2)9-13(10-17(3,4)21-16)20-15(23)14(22)19-12-7-5-11(18)6-8-12/h5-8,13,21H,9-10H2,1-4H3,(H,19,22)(H,20,23)
|
| Chemical Name |
N'-(4-chlorophenyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)oxamide
|
| Synonyms |
NBD556; NBD 556; NBD-556
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~98.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9599 mL | 14.7995 mL | 29.5989 mL | |
| 5 mM | 0.5920 mL | 2.9599 mL | 5.9198 mL | |
| 10 mM | 0.2960 mL | 1.4799 mL | 2.9599 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
